Simulating transplantation of donor bone-cartilage plugs for large chondral and osteochondral defects
Osteochondral allograft transplantation (OCA) is reserved for lesions that classic cartilage-only procedures cannot fix — defects large enough, or deep enough into the subchondral bone, that marrow-stimulation or cell-based resurfacing would leave an unsupported, structurally unstable repair. A single fresh composite plug restores both the articular surface and the bone beneath it in one operation.
The decision to pursue osteochondral allograft rather than a cartilage-only procedure hinges on two questions: how large is the chondral surface defect, and how deep is the associated bone loss?
Marrow-stimulation techniques (microfracture) and cell-based resurfacing (autologous chondrocyte implantation, ACI) are designed to regenerate a cartilage surface over intact, well-vascularized subchondral bone. When the defect exceeds roughly 2–4 cm² in surface area, or when more than 6–8 mm of subchondral bone is missing or structurally compromised, these techniques no longer have an adequate bony foundation to build on. Filling only the chondral component while leaving a bony void beneath it predisposes the repair to early mechanical failure, subsidence, and progressive collapse of the articular surface.
Osteochondral allograft solves this by transplanting a unified composite plug — hyaline cartilage still attached to its native subchondral and cancellous bone — that reconstructs the joint surface and its structural support simultaneously.
Several distinct clinical scenarios converge on the same solution:
• Osteochondritis dissecans (OCD) with bone loss: a segment of subchondral bone loses its blood supply and separates from the underlying condyle, often taking the overlying cartilage with it. Once the fragment is unsalvageable, the resulting crater has no bony floor for a cartilage-only repair to sit on.
• Avascular necrosis (AVN): loss of blood supply to a segment of subchondral bone (idiopathic, steroid-associated, or post-traumatic) causes bone collapse and secondary cartilage failure over a variable area.
• Osteochondral fracture or traumatic impaction: shear or impact injury shears cartilage away together with a fragment of subchondral bone, most commonly at the femoral condyle or patella after a dislocation event.
• Failed prior cartilage repair: microfracture and ACI can fail over time, sometimes leaving intralesional osteophytes, sclerotic or cystic subchondral bone, and further cartilage thinning. Allograft is frequently used as the salvage procedure of choice in this setting.
Osteochondral autograft transfer (OATS/mosaicplasty) harvests small cylindrical plugs from a low-weight-bearing part of the patient's own joint and transplants them into the defect — avoiding any donor-tissue or immune considerations entirely. But autograft is fundamentally volume-limited: the healthy, non-weight-bearing donor sites available in a single joint can only supply a few square centimeters of tissue before donor-site morbidity (pain, subsequent cartilage wear at the harvest site) becomes a real cost.
For defects beyond roughly 2–3 cm², or when multiple large plugs would be required, harvesting enough autograft tissue is either impossible or unacceptably damaging to otherwise healthy cartilage elsewhere in the joint. Allograft removes this ceiling: a size-matched cadaveric donor can supply a plug — or several plugs — precisely matched to the defect, with no additional injury to the patient's own joint surfaces.
The clinical decision point is rarely "allograft vs. nothing" — it is allograft vs. an autograft procedure that would either be too small to fill the defect or would create a second problem at the donor site. Allograft trades a small, well-screened risk of donor tissue for a complete, appropriately sized reconstruction.
Unlike almost every other transplanted tissue, osteochondral allograft cartilage cannot be frozen and thawed for use — freezing kills the resident chondrocytes, and dead chondrocytes cannot maintain the cartilage matrix over time. Fresh allografts are therefore harvested, screened, and transplanted within a narrow window, with graft quality declining continuously from the moment of donor procurement.
Fresh osteochondral allografts are recovered from deceased donors through accredited tissue banks under strict eligibility protocols modeled on those used for solid organ and other tissue donation. Donor screening includes a detailed medical and social history review, serologic testing (HIV, hepatitis B/C, syphilis), nucleic acid testing (NAT) to shorten the diagnostic window period, and microbial culture of the recovered tissue itself.
Recovery must occur within a defined post-mortem interval, and the graft is transported and processed under sterile, temperature-controlled conditions. Because the tissue is never frozen, terminal sterilization methods (irradiation, chemical sterilants) that would damage chondrocyte viability are generally avoided — screening and sterile recovery technique, rather than post-hoc sterilization, are what keep fresh grafts safe.
Cartilage and bone fail differently after transplantation, and that difference dictates the entire processing philosophy.
Bone has no long-term requirement for donor cell survival: it is a mineralized scaffold that the host will eventually resorb and rebuild through creeping substitution (see Stage 4), replacing dead donor bone with living host bone over months. Osseous incorporation is fundamentally a remodeling process, not a cell-survival problem.
Cartilage is the opposite. It is avascular and depends entirely on its resident chondrocytes to synthesize and maintain the collagen-proteoglycan matrix that gives cartilage its mechanical properties. There is no blood supply to bring in replacement cells, and no host remodeling process analogous to creeping substitution for hyaline cartilage — once the donor chondrocytes die, the matrix they were maintaining begins to degrade and cannot be regenerated. A graft can be perfectly sterile and structurally intact and still fail years later purely because too few of its original chondrocytes survived storage and transplantation.
This is why fresh, never-frozen storage is non-negotiable: cryopreservation reliably kills the great majority of chondrocytes, producing a graft that is immunologically and structurally sound but biologically inert at the cartilage surface.
Chondrocyte viability declines progressively from the moment of donor death and tissue recovery, even under optimal 4°C storage in physiologic media. Viability assays (commonly fluorescent live/dead staining) are used to confirm that a graft remains above the minimum threshold generally considered necessary for durable clinical performance — often cited around 70% viable cells — before it is released for implantation.
Because viability keeps falling throughout the storage period, tissue banks and treating surgeons work against a real clock: a graft recovered and matched to a specific recipient must be scheduled for implantation within a defined window (commonly on the order of a few weeks, depending on the bank's protocol and storage medium), after which declining viability makes the graft unsuitable for use even though it remains sterile and structurally intact. This urgency is a defining logistical feature of osteochondral allografting — surgery is scheduled around graft availability, not purely around the patient's calendar.
Bone only needs to be incorporated; cartilage needs to still be alive. That single distinction explains nearly every processing and scheduling decision in osteochondral allografting — from the ban on freezing, to viability testing, to the pressure to implant within days to a few weeks of donor recovery.
A structurally sound graft is only useful if it fits. Osteochondral allografting demands precise geometric matching between donor and recipient — in condyle size, surface curvature, and plug diameter — followed by a surgical technique built around interference (press) fit to achieve immediate mechanical stability without hardware.
Before a suitable donor graft can even be requested, the recipient defect and surrounding native anatomy must be characterized. Preoperative CT or MRI is used to measure the dimensions and radius of curvature of the affected condyle (or other articular surface), which are then compared against a tissue bank's catalog of available donor specimens — matched, where possible, by condyle size, side (medial/lateral, left/right knee), and overall joint dimensions.
Because fresh allografts must be used within a limited window and are sourced from a finite donor pool, size-matching is as much a logistics problem as a surgical-planning one: the ideal donor may not be immediately available, requiring the surgical team to balance geometric precision against the urgency created by declining graft viability.
The most common technique uses cylindrical coring reamers to prepare both the recipient defect and the donor graft to matching diameters. The recipient socket is reamed to a controlled depth through the defect and into healthy subchondral bone, restoring a clean cylindrical cavity with viable bleeding bone at its base. A matching cylindrical dowel is then cored from the donor condyle at the corresponding anatomic location, preserving its native cartilage cap and an appropriate depth of underlying cancellous bone.
The donor dowel is fashioned very slightly oversized relative to the recipient socket (an interference or "press" fit, commonly on the order of half a millimeter to about one millimeter). Gentle impaction seats the plug flush with the surrounding native articular surface, where the interference fit provides immediate mechanical stability — holding the graft in place without screws or pins while creeping substitution gradually achieves true biologic fixation over the following months.
Not every defect is a clean circle. For larger, shallower defects or those with irregular, non-cylindrical borders, a shell (or "shell allograft") technique may be used instead — the donor cartilage and a thin layer of subchondral bone are shaped freehand to match the recipient defect contour, rather than cored as a simple cylinder.
When a single circular defect is too large for one dowel of appropriate size, or when the defect footprint is itself irregular, surgeons often place two (or occasionally more) overlapping or adjacent circular dowels — colloquially the "snowman" technique — to cover the full area while still using standard cylindrical coring instrumentation. Each plug is press-fit individually, and their edges are positioned to minimize any remaining gap of exposed native (non-grafted) bone between them.
Precise size-matching and interference fit are what let an osteochondral allograft function immediately after implantation, before any biologic incorporation has occurred — the mechanical stability of a well-executed press fit buys the graft the months it needs for creeping substitution to complete the job.
Osteochondral allografts occupy an unusual immunologic middle ground. The cartilage component behaves almost as if it were the patient's own tissue, provoking little immune response and requiring no systemic immunosuppression — while the bone component is gradually recognized, resorbed, and rebuilt by the host over many months in a process called creeping substitution, during which the graft is biomechanically at its most vulnerable.
Solid organ transplantation requires careful donor-recipient immune matching and lifelong immunosuppression to prevent rejection, because transplanted vascularized tissue exposes donor cell-surface antigens directly to the host immune system through the bloodstream.
Articular cartilage is fundamentally different: it is avascular and aneural, and its chondrocytes are physically sequestered within a dense extracellular matrix of collagen and proteoglycans that they themselves secrete. This matrix substantially limits direct contact between donor cell-surface antigens and the host's circulating immune cells and antibodies. The practical consequence is that osteochondral allografts — unlike kidneys, livers, or hearts — do not require HLA matching, crossmatching, or systemic immunosuppressive drugs. Overt clinical rejection of the cartilage component is rare, which is part of what makes fresh allografting a viable outpatient-adjacent orthopedic procedure rather than a transplant-medicine undertaking.
The subchondral and cancellous bone within the graft is a different story immunologically and biologically. Even though the transplanted bone does not require the same viability that cartilage does, it is still foreign tissue that the host will gradually replace through a well-described process called creeping substitution.
Over a period commonly spanning roughly six months to two years (and sometimes longer for larger grafts), host osteoclasts resorb the dead donor trabecular bone from the periphery and base of the graft inward, while host osteoblasts lay down new, living, host-derived bone in its place — advancing progressively from the graft-host bony interface toward the cartilage-bone junction. This is the same fundamental remodeling process seen in large structural bone allografts elsewhere in orthopedics, simply operating on a smaller composite plug.
During the active remodeling window, the graft is biomechanically vulnerable: the interface between still-donor and newly-incorporated bone can be weaker than either fully-donor or fully-host bone alone, which is one reason surgeons counsel a graduated, protected return to full weight-bearing and impact activity over this period rather than immediate unrestricted loading.
While the graft's bony base ultimately achieves biologic fixation through creeping substitution, the cartilage cap does not have an analogous repair mechanism at its lateral margins — the boundary where donor cartilage meets the patient's native host cartilage around the rim of the defect.
Because mature hyaline cartilage has essentially no capacity for self-repair once it is separated (no blood supply to deliver reparative cells, and adult chondrocytes have limited proliferative and migratory capacity), the seam between graft and host cartilage frequently remains incompletely integrated — sometimes bridged by fibrocartilage or a thin fibrous interface rather than a seamless continuation of hyaline matrix. This lateral integration gap is generally not thought to compromise the graft's central weight-bearing function, but it remains an active area of research, with approaches under investigation including growth-factor and biologic adjuncts, tissue adhesives/sealants applied at the margin, and modified surgical techniques intended to improve edge-to-edge cartilage apposition at the time of implantation.
The graft's two tissue components age on completely different clocks: the bone is a remodeling problem that resolves over roughly one to two years as the host rebuilds it from within, while the cartilage cap is essentially fixed at implantation — its fate is decided almost entirely by how many chondrocytes were still alive when it went in.
Osteochondral allografting has accumulated some of the longest-term outcome data of any cartilage restoration technique, with survivorship extending well past a decade in many published series — particularly valuable for exactly the large, bone-involving defects where cell-based and marrow-stimulation techniques tend to be least durable.
Multiple published series — particularly for femoral condyle osteochondral allografts in the knee — report graft survivorship (freedom from graft failure or conversion to arthroplasty) in the range of roughly 80–85% at 10 years, with some well-followed cohorts extending to 15, 20, or more years and continuing to show durable function in a substantial majority of patients. This depth of long-term follow-up is relatively unusual among cartilage restoration procedures and gives surgeons and patients a clearer picture of realistic long-term expectations than is available for many newer techniques.
Patient-reported outcome improvements (pain, function, return to activity) are generally well maintained over this same horizon in successful grafts, and many published cohorts specifically include young, athletically active patients who were able to return to sport or high-demand activity after recovery.
The durability of osteochondral allografting comes with real practical costs relative to autograft- or cell-based alternatives:
• Tissue availability and cost: fresh, size-matched donor grafts are a finite and relatively expensive resource, sourced through accredited tissue banks with limited supply, and unlike an autograft or a cultured cell product, they cannot simply be manufactured on demand.
• Size-matching logistics: because grafts must be used fresh within a limited window, scheduling a case is contingent on a suitably matched donor becoming available at a compatible time — occasionally creating delays or requiring acceptance of an imperfect size match.
• Disease transmission risk: modern serologic and nucleic acid testing has made allograft-associated disease transmission extremely rare, but — as with any allogeneic tissue — it is not driven to exactly zero, and this small residual risk is part of informed consent.
• Technical demand: achieving an accurate press fit, correct graft depth, and appropriate surface contour restoration requires meticulous intraoperative technique; a poorly fit graft (proud, recessed, or malrotated) can compromise both short-term stability and long-term joint mechanics.
Cartilage restoration is typically approached as a graduated algorithm rather than a single default procedure:
• Small, shallow chondral-only defects: marrow-stimulation (microfracture) or cell-based resurfacing (ACI/MACI) are often first-line, since they are less invasive and preserve donor tissue for later use if needed.
• Small-to-moderate defects with adequate bone stock, in patients wanting to avoid allograft tissue: osteochondral autograft transfer (OATS/mosaicplasty) can be appropriate where a small enough volume of tissue is needed.
• Large chondral or osteochondral defects, especially with meaningful subchondral bone loss, OCD, AVN, or failure of a prior marrow-stimulation/cell-based repair: osteochondral allograft is frequently the preferred option, precisely because it is the only widely used technique that reliably reconstructs both the cartilage surface and a substantial bony defect in a single procedure, without the volume limitations of autograft.
Rather than competing head-to-head across all indications, these techniques are largely complementary — selected according to defect size, depth of bone involvement, and whether the patient has already exhausted less invasive options.
Osteochondral allograft is best understood not as a universal cartilage-repair solution but as the technique specifically suited to the cases other methods cannot reach: large defects with genuine bone loss, where a cell-based repair or marrow-stimulation procedure would be built on an inadequate bony foundation from the start.